🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)Oral semaglutide 50mg Phase 3 — OASIS program results

Oral semaglutide 50mg Phase 3 — OASIS program results

Dr.Martinez Mon, Jun 8, 2026 at 9:57 AM 16 replies 352 viewsPage 1 of 4
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Jun 8, 2026 at 9:57 AM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.

Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.

What I actually want to know is how much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly. I have searched first, so if this is covered somewhere point me at it and I will read it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
39 9AttorneyGrant, DebRD_ATL, KristenIndy and 36 others
Reply Quote Save Share Report
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Jun 8, 2026 at 9:59 AM#2
Dr.Martinez said:
Orforglipron is the more interesting oral story because it is not a peptide at all.

No disagreement with Dr.Martinez. One condition attached. The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to get there because almost none of the tablet is absorbed. The dose numbers are not comparable across routes and quoting them side by side confuses people.

Happy to go further on any of that.

38 8tyler_CSCS, VanRx_Mike, steve_okc and 35 others
Reply Quote Save Share Report
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
Jun 8, 2026 at 10:01 AM#3
Dr.Martinez said:
Orforglipron is the more interesting oral story because it is not a peptide at all.

I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.

37 7PharmHunterJen, TomTeleRx, DoseLogDan and 34 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
sophie_paris
Member
212
890
Nov 2024
Paris, FR
Jun 8, 2026 at 10:03 AM#4

Taking the question as asked, rather than the general version of it. Oral semaglutide is absorbed in the stomach with the help of SNAC, which locally raises pH and protects the peptide long enough to cross. That mechanism is fragile: bioavailability is roughly 1% and highly sensitive to gastric contents, so a mouthful of coffee genuinely changes the exposure. This is why the label wants 30 minutes and no more than half a glass of plain water.

Last edited: Jun 8, 2026 at 3:03 PM
36 6AussieAnna, BethLabQueen, ChrisMacros and 33 others
Reply Quote Save Share Report
wendy_avl
Member
245
1,123
Oct 2024
Asheville, NC
Jun 8, 2026 at 10:14 AM#5
Dr.GutHealth said:
The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to…

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

35 5RickReta_CO, PharmHunterJen, TomTeleRx and 32 others
Reply Quote Save Share Report

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
0.25mg → 2.4mg titration: optimal schedule based on clinical data6 replies
Semaglutide and GFR improvement — FLOW trial renal endpoints15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register